Literature DB >> 33276089

Insight into the roles of CCR5 in learning and memory in normal and disordered states.

Deanna Necula1, Cecile Riviere-Cazaux2, Yang Shen3, Miou Zhou4.   

Abstract

As cognitive impairments continue to rise in prevalence, there is an urgent need to understand the mechanisms of learning and memory in normal and disordered states. C-C chemokine receptor 5 (CCR5) has been implicated in the regulation of multiple forms of learning and memory via its regulation on learning-related cell signaling and neuronal plasticity. As a chemokine receptor and a co-receptor for HIV, CCR5's role in immune response and HIV-associated neurocognitive disorder (HAND) has been widely studied. In contrast, CCR5 is less understood in cognitive deficits associated with other disorders, including Alzheimer's disease (AD), stroke and certain psychiatric disorders. A broad overview of the present literature shows that CCR5 acts as a potent suppressor of synaptic plasticity and learning and memory, although a few studies have reported the opposite effect of CCR5 in stroke or AD animal models. By summarizing the current literature of CCR5 in animal and human studies of cognition, this review aims to provide a comprehensive overview of the role of CCR5 in learning and memory in both normal and disordered states and to discuss the possibility of CCR5 suppression as an effective therapeutic to alleviate cognitive deficits in HAND, AD, and stroke.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33276089     DOI: 10.1016/j.bbi.2020.11.037

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  9 in total

Review 1.  Targeting C-C Chemokine Receptor 5: Key to Opening the Neurorehabilitation Window After Ischemic Stroke.

Authors:  Yi-Qi Feng; Zhen-Zhen Xu; Yan-Ting Wang; Yue Xiong; Wanli Xie; Yu-Yao He; Lu Chen; Guo-Yang Liu; Xia Li; Jie Liu; Qingping Wu
Journal:  Front Cell Neurosci       Date:  2022-04-28       Impact factor: 6.147

2.  Therapeutic Mechanism and Key Alkaloids of Uncaria rhynchophylla in Alzheimer's Disease From the Perspective of Pathophysiological Processes.

Authors:  Peng Zeng; Hong-Fei Su; Chao-Yuan Ye; Shuo-Wen Qiu; Qing Tian
Journal:  Front Pharmacol       Date:  2021-12-15       Impact factor: 5.810

3.  CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab.

Authors:  Xiao L Chang; Helen L Wu; Gabriela M Webb; Meenakshi Tiwary; Colette Hughes; Jason S Reed; Joseph Hwang; Courtney Waytashek; Carla Boyle; Cleiton Pessoa; Andrew W Sylwester; David Morrow; Karina Belica; Miranda Fischer; Scott Kelly; Nader Pourhassan; Rachele M Bochart; Jeremy Smedley; Christopher P Recknor; Scott G Hansen; Jonah B Sacha
Journal:  Front Immunol       Date:  2021-11-19       Impact factor: 8.786

Review 4.  Cellular, synaptic, and network effects of chemokines in the central nervous system and their implications to behavior.

Authors:  Joanna Ewa Sowa; Krzysztof Tokarski
Journal:  Pharmacol Rep       Date:  2021-08-26       Impact factor: 3.024

5.  Identification of Molecular Signatures and Candidate Drugs in Vascular Dementia by Bioinformatics Analyses.

Authors:  Jun Shu; Wenshi Wei; Li Zhang
Journal:  Front Mol Neurosci       Date:  2022-02-11       Impact factor: 5.639

6.  A CCR5 antagonist, maraviroc, alleviates neural circuit dysfunction and behavioral disorders induced by prenatal valproate exposure.

Authors:  Yasuhiro Ishihara; Tatsuya Honda; Nami Ishihara; Kaede Namba; Makiko Taketoshi; Yoko Tominaga; Mayumi Tsuji; Christoph F A Vogel; Takeshi Yamazaki; Kouichi Itoh; Takashi Tominaga
Journal:  J Neuroinflammation       Date:  2022-07-29       Impact factor: 9.587

Review 7.  Role of Chemokines in the Development and Progression of Alzheimer's Disease.

Authors:  Jakub Wojcieszak; Katarzyna Kuczyńska; Jolanta B Zawilska
Journal:  J Mol Neurosci       Date:  2022-07-12       Impact factor: 2.866

8.  Novel small synthetic HIV-1 V3 crown variants: CCR5 targeting ligands.

Authors:  Anju Krishnan Anitha; Pratibha Narayanan; Neethu Ajayakumar; Krishnankutty Chandrika Sivakumar; Kesavakurup Santhosh Kumar
Journal:  J Biochem       Date:  2022-09-05       Impact factor: 3.241

Review 9.  The role of CCR5 in HIV-associated neurocognitive disorders.

Authors:  Cecile Riviere-Cazaux; Jessica Cornell; Yang Shen; Miou Zhou
Journal:  Heliyon       Date:  2022-07-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.